Simufilam found safe in review of ongoing Alzheimer’s clinical trials
WEB20 hours ago · In a previous Phase 2 clinical trial (NCT04388254), which enrolled more than 200 people with mild to moderate Alzheimer’s disease, 47% of the patients treated with simufilam (100 mg twice daily) for a year saw improvements in their cognitive function.. In the RETHINK-ALZ trial, the 804 participants were randomly assigned to receive 100 mg of simufilam, or a placebo, twice daily for one year.
Cassava Sciences Announces Completion of an Interim Safety …
WEB3 days ago · Today’s news follows interim safety MRI data announced in October 2023, which suggests simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities (ARIA).
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
WEBMar 14, 2023 · Simufilam, an experimental drug that targets filamin A, improved cognition in 47% of Alzheimer's patients with mild-to-moderate disease after one year of treatment. The drug also reduced tau levels, dementia-related behaviors, and depression in patients, and was safe and well tolerated.
Topline results of Phase 3 studies of simufilam for Alzheimer's...
WEBFeb 8, 2024 · Simufilam is an experimental oral therapy that targets filamin A, a protein involved in Alzheimer's disease. Two Phase 3 studies with 1,929 patients are expected to report top-line results by the end of 2023 and 2025, respectively.
No Decline in Cognition Scores in Patients with Mild Alzheimer's ...
WEBThis news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of …
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
WEBOct. 14, 2023. A neuroscientist whose studies undergird an experimental Alzheimer’s drug was “reckless” in his failure to keep or provide original data, an offense that “amounts to significant...
Cassava Sciences Announces Science Publication That Confirms …
WEBSummary of New Research A team of researchers led by Dr. Ralf Jockers at the Cochin Institute (Paris, France) used an amyloid binding assay to measure the ability of …
Cassava Sciences’ Simufilam Improves Cognition and Behavior in ...
WEBThis news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of …
Cassava Sciences Announces Positive Top-Line Clinical
WEBADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
WEB1 day ago · Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. ... I’m sure this news is ...
- Some results have been removed
Skip to content